pFendoNA2S
(Plasmid
#174730)
-
PurposeExpresses GFP-endoNA2-S706A fusion protein for detection of polysialic acid. The endoNA2-S706A is a noncatalytic endosialidase that lacks the ability for releasing its C-terminal chaperone domain.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 174730 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepFEndoNA2
-
Backbone manufacturerFinne lab
- Backbone size w/o insert (bp) 7102
- Total vector size (bp) 7102
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameendoNA2-S706A
-
SpeciesEscherichia phage PK1A2
-
Insert Size (bp)2403
-
MutationChanged Serine 706 to Alanine
-
GenBank IDMG004687.1
Cloning Information
- Cloning method Ligation Independent Cloning
- 5′ sequencing primer CCCGAAAAGTGCCACCTG
- 3′ sequencing primer GTTCTGAGGTCATTACTGG (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This plasmid can be amplified and maintained in ampicillin-sensitive E. coli strains that harbor the lacIq mutation (such as XL1 Blue and JM109) or carries the pREP4 repressor plasmid (such as M15 [pREP4]).
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pFendoNA2S was a gift from Jukka Finne (Addgene plasmid # 174730 ; http://n2t.net/addgene:174730 ; RRID:Addgene_174730) -
For your References section:
Design of a cytotoxic neuroblastoma-targeting agent using an enzyme acting on polysialic acid fused to a toxin. Lehti TA, Pajunen MI, Jokilammi A, Korja M, Lilie H, Vettenranta K, Finne J. Mol Cancer Ther. 2021 Jul 26. pii: 1535-7163.MCT-20-1031. doi: 10.1158/1535-7163.MCT-20-1031. 10.1158/1535-7163.MCT-20-1031 PubMed 34315766